Saito et al., 2013 - Google Patents
11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumorsSaito et al., 2013
View PDF- Document ID
- 5233398926716597251
- Author
- Saito T
- Maruyama T
- Muragaki Y
- Tanaka M
- Nitta M
- Shinoda J
- Aki T
- Iseki H
- Kurisu K
- Okada Y
- Publication year
- Publication venue
- American Journal of Neuroradiology
External Links
Snippet
BACKGROUND AND PURPOSE: Oligodendroglial tumors with 1p/19q LOH are known to show longer patient survival than those without 1p/19q LOH, but the reason for this clinical difference has not been elucidated, to our knowledge. This study was designed to clarify …
- 201000010133 oligodendroglioma 0 title abstract description 53
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saito et al. | 11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors | |
| Villanueva-Meyer et al. | MRI features and IDH mutational status of grade II diffuse gliomas: impact on diagnosis and prognosis | |
| Xing et al. | Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging | |
| Jain et al. | In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas | |
| Mills et al. | Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? | |
| Kato et al. | Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity | |
| Kickingereder et al. | Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma | |
| Jain | Perfusion CT imaging of brain tumors: an overview | |
| Hilario et al. | The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas | |
| Hilario et al. | A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas | |
| Tsien et al. | Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma | |
| Togao et al. | Differentiation of high-grade and low-grade diffuse gliomas by intravoxel incoherent motion MR imaging | |
| Ellingson et al. | Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma | |
| Schmainda et al. | Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial | |
| Ellingson et al. | Graded functional diffusion map–defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab | |
| Ellingson et al. | Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials | |
| Maia et al. | MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas | |
| Barajas et al. | Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma | |
| Hamstra et al. | Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival | |
| Gupta et al. | Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma | |
| Law et al. | Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade | |
| Piccardo et al. | Advanced MR imaging and 18 F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas | |
| Qiao et al. | Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma | |
| Foltyn et al. | T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology | |
| Ballesio et al. | Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: correlation with tumor biological subtypes and pathological response after therapy |